Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin effect on renal glucose transport with empagliflozin in type 2 diabetes
2015-005727-80Phase 2Completed
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin and human insulin in type 2 diabetes mellitus (T2DM), sponsored by Fondazione Toscana Gabriele Monasterio. Primary endpoint: Urinary glucose excretion during CT period. Started Jan 2022; status: completed.
02
Drugs
empagliflozinhuman insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005727-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005727-80.